Virological and Molecular Profile of People Living with the Human Immunodeficiency Virus Starting Dolutegravir Based Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo

Bongenya, Berry Ikolango; Tshinguta, Charlotte L.; Sombo, Marie-Thérèse A. S.; Bumoko, Guy M. M.; Kabengele, Benoit O.; Mesia, Gauthier K.; Kamangu, Erick Ntambwe

doi:10.4236/wja.2023.133008

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virological failure rate of first-line treatment according to the recommendations of the World Health Organization (WHO) is 40.33%, with 17.75% of patients experiencing major failure (greater than 5.0 log10). These data are justifiable by the fact that more than half of patients start ART with a poor prognosis of remission [5] [25] [26]. At M6 of this cohort, the failure rate of 40.33% is higher than those presented for the city of Kinshasa in previous years [27] [28].…”

Section: Discussionmentioning

confidence: 99%

Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Bongenya,

Kabengele,

Sombo

et al. 2023

AID

Self Cite

View full text Add to dashboard Cite

Introduction: The sixth month appointment (M6) is crucial because at the start of the ART course, it is an indicator of the prognosis of the evolution of care and decision-making on the continuity of treatment. Objective: The objective of this study is therefore to present the profile of People Living with HIV under treatment with Dolutegravir 6 months after starting ART in Kinshasa. Methods: The present study is a cross-sectional view at M6 of a prospective cohort to determine the profile of People Living with HIV (PLHIV) after 6 months of ARV Treatment (ART) in Kinshasa, DRC. During the M6 appointment, from April to August 2022, a sample of 5 ml of blood was taken for the various analyzes from all HIV patients included. The collection of sociodemographic data as well as biological and clinical data was carried out under the same conditions as at inclusion. The parameters recorded during M6 were: age, sex, and religion, level of study, marital status, profession, socio-economic level, height, weight, Body Mass Index (BMI), clinical profile, opportunistic infections as well as biochemical and molecular assessment. Results: In M6, 62 patients were registered including 38 women (61.3%), thus giving a sex ratio of 1.58 in favor of women. Fifty-seven (57) patients did not How to cite this paper: Bongenya, B.I.,

show abstract

Section: Discussionmentioning

confidence: 99%

Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Bongenya,

Kabengele,

Sombo

et al. 2023

AID

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hence, the virological failure rate of first-line treatment according to the recommendations of the World Health Organization (WHO) is 50.0%, with 10.0% of patients experiencing major failure (greater than 5 .0 log 10 RNA copies/mL). These data are justifiable by the high rate of patients with a poor virological prognosis at the start of ART [4] [16]. Different studies had shown that there is a strong correlation between VL at the inclusion and at M12 [4] [16].…”

Section: Discussionmentioning

confidence: 99%

“…After collection, the samples were taken to the Molecular Biology laboratory of the Department of Basic Sciences at the Faculty of Medicine of the University of Kinshasa (UNIKIN) where the molecular biology analyses were carried out under the conditions previously described [4] [5].…”

Section: Biological Analyzesmentioning

confidence: 99%

Virological Profile of People Living with HIV after 12 Months of Treatment with Dolutegravir in Kinshasa

Bongenya,

Sombo,

Bumoko

et al. 2023

WJA

Self Cite

View full text Add to dashboard Cite

Context: The evaluation of plasma Viral Load constitutes an indicator of the progression of the infection, the effectiveness and the tolerance of the treatment. Objective: The objective of this study is to present the virological profile of Patients Living with HIV (PLHIV) after 12 months of AntiRetro Viral Treatment (ART) based on Dolutegravir (DTG) in Kinshasa. Method: The present study is a cross-sectional view of the virological profile of the twelfth month of a prospective cohort of PLHIV at M12 of DTG-based ART in Kinshasa. During the M12 appointment, a blood sample was taken for Molecular Biology analyses from all PLHIV included. Result: During the M12 appointment, 28 patients were registered, including 16 (57.1%) women. Nine (9) patients (45.0%) had an undetectable Viral Load (VL). The median VL value was 3.18 log 10 RNA copies/mL (1530 RNA copies/mL). The mutations K65R, T69P/N, K70R and M184V have been listed as mutations conferring resistance to Nucleotide Reverse Transcriptase Inhibitors. No mutations associated with Dolutegravir were observed at M12. Conclusion: After 12 months of AntiRetroViral Treatment based on Dolutegravir, half of the Patients on first-line ART are in a state of virological failure.

show abstract

Virological and Molecular Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Bongenya,

Tshinguta,

Kabengele

et al. 2023

WJA

Self Cite

View full text Add to dashboard Cite

Context: The appointment of the M6 is crucial because it is an indicator of the prognosis of the evolution of the care and the decision-making on the continuation of the AntiRetroViral Treatment. Objective: The objective of this study is therefore to present the virological and molecular profile of People Living with HIV under treatment with Dolutegravir 6 months after being put on ART in Kinshasa. Methods: The present study is a cross-sectional view at the sixth month of a prospective cohort to determine the virological and molecular profile of People Living with HIV (PLHIV) after 6 months of ART based on Dolutegravir (DTG) in Kinshasa. A sample of 5 mL of blood was taken from all HIV patients included. The collection of biological data was carried out under the same conditions as at inclusion. After extraction, Quantitative Real-Time PCR was carried out to determine the quantity of HIV RNA in the samples according to the protocols previously described. Reverse Transcription PCR (RT-PCR) and Nested PCR were carried out to amplify the regions of interest for Protease and Reverse Transcriptase for sequencing. Results: The median VL value was 2.92 log 10 RNA copies/mL. With 17.75% of patients experiencing major failure of first-line treatment. Subtype A is dominant with 13 cases (20.98%); followed by CRF_02AG (16.13%), subtypes C (14.52%), D (9.68%) and K (6.45%). The K65R (3 cases), T69P/N (6 cases), K70R (9 cases) and M184V (8 cases) mutations were listed as existing muta-

show abstract

Virological and Molecular Profile of People Living with the Human Immunodeficiency Virus Starting Dolutegravir Based Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo

Cited by 3 publications

References 13 publications

Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Virological Profile of People Living with HIV after 12 Months of Treatment with Dolutegravir in Kinshasa

Virological and Molecular Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Contact Info

Product

Resources

About